<DOC>
	<DOC>NCT00570752</DOC>
	<brief_summary>The purpose of the study is to determine whether a p38 kinase inhibitor reduces inflammation in atherosclerotic plaque</brief_summary>
	<brief_title>Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>History of documented atherosclerosis LDL between 70 and 130 mg/dL Patients receiving stable low to moderatedose statin BMI 1837 kg/mÂ² Must be able to swallow tablets Must be able to medically tolerate the procedures, contrast medium, and medications involved Statin intolerance Renal impairment (serum creatinine &gt; 1.5 mg/dL) History of chronic viral hepatitis or other liver dysfunction Major infection requiring hospitalization or receipt of IV antibiotics due to an infection within 2 months prior to initiation of study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>